ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

被引:794
作者
Arteaga, Carlos L. [1 ]
Engelman, Jeffrey A. [2 ]
机构
[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
[2] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
关键词
EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; CELL LUNG-CANCER; ADVANCED BREAST-CANCER; GENE COPY NUMBER; PERTUZUMAB PLUS TRASTUZUMAB; FACTOR-I RECEPTOR; ACQUIRED-RESISTANCE; NEOADJUVANT CHEMOTHERAPY; ADJUVANT TRASTUZUMAB;
D O I
10.1016/j.ccr.2014.02.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ERBB receptors were linked to human cancer pathogenesis approximately three decades ago. Biomedical investigators have since developed substantial understanding of the biology underlying the dependence of cancers on aberrant ERBB receptor signaling. An array of cancer-associated genetic alterations in ERBB receptors has also been identified. These findings have led to the discovery and development of mechanism-based therapies targeting ERBB receptors that have improved outcome for many cancer patients. In this Perspective, we discuss current paradigms of targeting ERBB receptors with cancer therapeutics and our understanding of mechanisms of action and resistance to these drugs. As current strategies still have limitations, we also discuss challenges and opportunities that lie ahead as basic scientists and clinical investigators work toward more breakthroughs.
引用
收藏
页码:282 / 303
页数:22
相关论文
共 219 条
[31]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[32]   Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers [J].
Dave, Bhuvanesh ;
Migliaccio, Ilenia ;
Gutierrez, M. Carolina ;
Wu, Meng-Fen ;
Chamness, Gary C. ;
Wong, Helen ;
Narasanna, Archana ;
Chakrabarty, Anindita ;
Hilsenbeck, Susan G. ;
Huang, Jian ;
Rimawi, Mothaffar ;
Schiff, Rachel ;
Arteaga, Carlos ;
Osborne, C. Kent ;
Chang, Jenny C. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) :166-173
[33]   The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers [J].
Diaz, Luis A., Jr. ;
Williams, Richard T. ;
Wu, Jian ;
Kinde, Isaac ;
Hecht, J. Randolph ;
Berlin, Jordan ;
Allen, Benjamin ;
Bozic, Ivana ;
Reiter, Johannes G. ;
Nowak, Martin A. ;
Kinzler, Kenneth W. ;
Oliner, Kelly S. ;
Vogelstein, Bert .
NATURE, 2012, 486 (7404) :537-540
[34]   Somatic mutations affect key pathways in lung adenocarcinoma [J].
Ding, Li ;
Getz, Gad ;
Wheeler, David A. ;
Mardis, Elaine R. ;
McLellan, Michael D. ;
Cibulskis, Kristian ;
Sougnez, Carrie ;
Greulich, Heidi ;
Muzny, Donna M. ;
Morgan, Margaret B. ;
Fulton, Lucinda ;
Fulton, Robert S. ;
Zhang, Qunyuan ;
Wendl, Michael C. ;
Lawrence, Michael S. ;
Larson, David E. ;
Chen, Ken ;
Dooling, David J. ;
Sabo, Aniko ;
Hawes, Alicia C. ;
Shen, Hua ;
Jhangiani, Shalini N. ;
Lewis, Lora R. ;
Hall, Otis ;
Zhu, Yiming ;
Mathew, Tittu ;
Ren, Yanru ;
Yao, Jiqiang ;
Scherer, Steven E. ;
Clerc, Kerstin ;
Metcalf, Ginger A. ;
Ng, Brian ;
Milosavljevic, Aleksandar ;
Gonzalez-Garay, Manuel L. ;
Osborne, John R. ;
Meyer, Rick ;
Shi, Xiaoqi ;
Tang, Yuzhu ;
Koboldt, Daniel C. ;
Lin, Ling ;
Abbott, Rachel ;
Miner, Tracie L. ;
Pohl, Craig ;
Fewell, Ginger ;
Haipek, Carrie ;
Schmidt, Heather ;
Dunford-Shore, Brian H. ;
Kraja, Aldi ;
Crosby, Seth D. ;
Sawyer, Christopher S. .
NATURE, 2008, 455 (7216) :1069-1075
[35]   FOLFOX4 With Cetuximab vs. UFOX With Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: The Randomized Phase II FUTURE Study [J].
Douillard, Jean-Yves ;
Zemelka, Tomasz ;
Fountzilas, George ;
Barone, Carlo ;
Schlichting, Michael ;
Heighway, Jim ;
Eggleton, S. Peter ;
Srimuninnimit, Vichien .
CLINICAL COLORECTAL CANCER, 2014, 13 (01) :14-U39
[36]   CLOSE SIMILARITY OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND V-ERB-B ONCOGENE PROTEIN SEQUENCES [J].
DOWNWARD, J ;
YARDEN, Y ;
MAYES, E ;
SCRACE, G ;
TOTTY, N ;
STOCKWELL, P ;
ULLRICH, A ;
SCHLESSINGER, J ;
WATERFIELD, MD .
NATURE, 1984, 307 (5951) :521-527
[37]   Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers [J].
Ebi, Hiromichi ;
Corcoran, Ryan B. ;
Singh, Anurag ;
Chen, Zhao ;
Song, Youngchul ;
Lifshits, Eugene ;
Ryan, David P. ;
Meyerhardt, Jeffrey A. ;
Benes, Cyril ;
Settleman, Jeffrey ;
Wong, Kwok-Kin ;
Cantley, Lewis C. ;
Engelman, Jeffrey A. .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (11) :4311-4321
[38]   Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235 [J].
Eichhorn, Pieter J. A. ;
Gili, Magui ;
Scaltriti, Maurizio ;
Serra, Violeta ;
Guzman, Marta ;
Nijkamp, Wouter ;
Beijersbergen, Roderick L. ;
Valero, Vanesa ;
Seoane, Joan ;
Bernards, Rene ;
Baselga, Jose .
CANCER RESEARCH, 2008, 68 (22) :9221-9230
[39]   ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines [J].
Engelman, JA ;
Jänne, PA ;
Mermel, C ;
Pearlberg, J ;
Mukohara, T ;
Fleet, C ;
Cichowski, K ;
Johnson, BE ;
Cantley, LC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) :3788-3793
[40]   MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].
Engelman, Jeffrey A. ;
Zejnullahu, Kreshnik ;
Mitsudomi, Tetsuya ;
Song, Youngchul ;
Hyland, Courtney ;
Park, Joon Oh ;
Lindeman, Neal ;
Gale, Christopher-Michael ;
Zhao, Xiaojun ;
Christensen, James ;
Kosaka, Takayuki ;
Holmes, Alison J. ;
Rogers, Andrew M. ;
Cappuzzo, Federico ;
Mok, Tony ;
Lee, Charles ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
SCIENCE, 2007, 316 (5827) :1039-1043